RxSight (RXST) to Release Earnings on Tuesday

RxSight (NASDAQ:RXST - Get Free Report) is anticipated to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect RxSight to post earnings of $0.10 per share and revenue of $40.23 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

RxSight Stock Performance

Shares of NASDAQ:RXST traded down $0.73 during midday trading on Friday, reaching $29.60. The company had a trading volume of 526,195 shares, compared to its average volume of 604,370. The company has a fifty day simple moving average of $33.29 and a two-hundred day simple moving average of $43.89. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -35.66 and a beta of 1.19. RxSight has a 1-year low of $26.29 and a 1-year high of $66.54.

Insider Activity at RxSight

In other RxSight news, Director Jesse Anderson Corley acquired 1,443 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average price of $31.18 per share, with a total value of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares in the company, valued at $44,992.74. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the completion of the sale, the director now owns 10,902 shares of the company's stock, valued at $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,506 shares of company stock valued at $567,456. Insiders own 9.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RXST shares. Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of RxSight in a research report on Monday, January 13th. Jefferies Financial Group began coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price objective on the stock. Stifel Nicolaus reduced their target price on RxSight from $40.00 to $35.00 and set a "hold" rating for the company in a report on Monday, January 13th. Wells Fargo & Company lowered their price target on RxSight from $42.00 to $40.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, UBS Group initiated coverage on RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $58.13.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.